INTRODUCTION
Diabetes complicating pregnancy is on the rise, especially in south Asian countries like India. This is due to increasing incidence of gestational diabetes mellitus [GDM] and lower age at onset of type 2 diabetes mellitus [T2DM] in India [1] Diet and insulin have been the main therapeutic agents for diabetic pregnancies for years. Oral hypoglycemic agents like glyburide and metformin have now been found to be useful and safe in pregnancy. Insulin therapy in pregnancy was considered best because of its effi cacy, inability to cross the placenta and fetal safety. However, frequent injections, risk of hypoglycemia and cost are some of the disadvantages that stimulated interest in trials of oral hypoglycemic drugs in pregnancy.
Objective
To compare the use of metformin with that of insulin in the management of diabetic pregnancies.
MATERIAL AND METHODS

Study design
In this prospective observational study, one obstetric unit used metformin for GDM and T2DM in pregnancy. The results were compared with patients of another unit using only insulin. Approval for the study was obtained from the ethical committee after obtaining informed consent from participants.
Patients diagnosed with GDM after 100 g oral glucose tolerance test (GTT) following a positive glucose challenge test (≥140 mg/ dL) with 50 g of oral glucose were included. GDM was diagnosed with 2 or more abnormal values in GTT as per Carpenter and Coustan's criterion [2] (fasting plasma glucose ≥95 mg/dL, at 1 hour ≥180 mg/dL, at 2 hours ≥155 mg/dl, at 3 hours ≥140 mg/dL). Women with T2DM in pregnancy and those with GDM who failed diet therapy of 1 week were recruited to receive either metformin or insulin therapy depending on the obstetric unit they belonged to. Diet therapy was advised by the same nutritionist for both the groups. Exclusion criteria were patients with deranged liver or kidney functions and those with type 1 diabetes. Metformin was given at a dose of 500 mg three times a day to a maximum of 2000 mg/day based on glycemic profi le.
Insulin was similarly started and titrated based on plasma glucose values. Intermediateacting insulin (Mixtard) was the insulin used, and short-acting insulin (Actrapid) was used whenever required. 
RESULTS
In this prospective study conducted over a period of 2 years (September 2004 to August 2006), 60 women with GDM and T2DM fulfi lled the inclusion criteria. Table 1 shows the comparison between 2 groups of diabetic mothers treated with metformin and insulin.
Both groups were comparable with respect to age, BMI, parity and the GTT values. T2DM women in both groups (2 in metformin group and 6 in insulin group) continued their preconception therapy through pregnancy. Bad obstetric history for this study was defi ned as history of previous two abortions or one fetal Glycemic profi les -before therapy, after 1 week of therapy and throughout pregnancyare depicted in Figure 1 . Though the values in the insulin group before therapy appear marginally higher, the difference was not statistically signifi cant (P= 0.08-0.69; 95% CI, 1.04-26.2). To avoid its infl uence on immediate sugar control, adjusted mean values (analysis of covariance) were used in both groups while comparing the glucose values after starting therapy. A significant reduction in adjusted mean glucose levels in the metformin group was noted as compared to the insulin group Considering individual patients, glycemic goal was reached by 24 (82%) and 13 (54%) women on metformin and insulin, respectively. This difference was statistically signifi cant (P=.024). Twelve (40%) patients on metformin and 18 (69%) patients on insulin (Pearson X 2 =4.29;P= 0.038) required repeated dose adjustments based on glycemic profile. Metformin thus showed more uniform control of sugars as compared to insulin. Two patients on metformin required additional small dose of insulin at around 36 weeks of gestation.
The incidence of maternal complications such as preeclampsia, UTI, vaginitis, polyhydramnios and preterm labor was comparable between the 2 groups (P= 0.12-1.00). There was no difference in the rate and indications for cesarean sections between the 2 groups. Total maternal weight gain in the metformin group (5.5 ± 2.9 kg) was signifi cantly less than that in the insulin group (7.4 ± 2.8 kg, P= 0.017).
There were no macrosomic babies. Shoulder dystocia was encountered in 1 baby weighing 3.3 kg in the metformin group. Cephalhematoma noted in the insulin group was after a normal vaginal delivery. Neonatal details [ Table 2 ] show that there were no major differences in neonatal morbidity except for NICU admission. The power of study calculated for NICU stay was 72%. Mean duration of stay for babies in the insulin group was 6.5 (2-20) days; and for babies in the metformin group, it was 2.5 days. Longer NICU stay in the insulin group was because of higher incidence of hyperbilirubinemia / hypoglycemia. Neonatal hypoglycemia significant enough to cause seizures was encountered in 1 baby in the insulin group. No baby had Apgar score <7 at birth, and there were no perinatal deaths. Except for 1 major cardiac anomaly requiring surgery in the insulin group for a mother with T2DM, all other anomalies were minor.
Maternal side effects [Table 2]
There was 1 case of gastritis with metformin, which was corrected with reduction of dose. There were no cases of diabetic ketoacidosis or lactic acidosis in this study. Two mothers in the insulin group had symptomatic hypoglycemia
Cost of therapy
Insulin therapy was considerably more expensive. Cost of therapy per patient per day varied between Rs. 6 and 12 for metformin. It was Rs. 30-145 for insulin, almost 5-to 10-fold even after excluding the cost of syringes and needles.
DISCUSSION
In this prospective study, we observed that metformin is an effective alternative to insulin in diabetic pregnant women. Insulin improves glycemic profi le but does not improve insulin resistance, an important feature of pregnancy, GDM and T2DM. Metformin being an insulin sensitizer targets insulin resistance without enhancing endogenous insulin production, in addition to reducing plasma insulin levels. Glycemic control throughout pregnancy and the number of women attaining glycemic goal were significantly better with metformin as compared to insulin in our population, where daily monitoring of glucose could not be done. Similar results have been noted in other studies. [3] Dose adjustments were required less often with metformin unlike intermediateacting insulin despite longer duration of action of the latter. Satisfactory glycemic profi le was obtained within 1 week with metformin. Coetzee et al. also noted that oral drugs if successful produce maternal normoglycemia within a short time whereas excellent control with insulin may take 2 to 3 weeks of adjustment. [4] Maternal and fetal complications were comparable in both groups except that the SGA babies were more in the insulin group. This has been noted with stringent control of diabetes earlier, but we are unable to explain this as the mean sugar values were comparatively higher in the insulin group. [5] Coetzee et al. tried metformin in 60 diabetic patients, majority of them being maturity onset and only 21 were GDM. [6] The failure rate in the former was 54% while in the latter it was 29%. This may be because 79% of their patients were overweight. This study also noted a higher incidence of neonatal hyperbilirubinemia though overall neonatal morbidity was low in the metformin group.
Hellmuth et al. noted a high incidence of preeclampsia and perinatal deaths with metformin. [7] On the contrary, it is now believed that metformin may reduce preeclampsia in GDM women by reducing the endothelial activation and maternal infl ammatory response of insulin resistance. [3, 8] We did not observe increased incidence of preeclampsia with metformin. There were no perinatal deaths in our study, and perinatal morbidity has been similar except for longer NICU stay for babies in the insulin group. Results of MiG trial showed that there was no difference in perinatal outcome in groups treated with metformin or insulin and that women preferred metformin to insulin. So far this has been the largest randomized trial, with 751 women, to assess the effi cacy and safety of metformin in women with GDM. [8] Advantages of metformin are its ease of administration and its low cost. This is beneficial in resource-poor populations. Disadvantages of insulin are problems of storage, the inconvenience of daily injections, besides increase in appetite and weight. Dosing of metformin is standardized, unlike insulin, and can be managed by obstetric specialists without the help of general physicians. Metformin does not cause hypoglycemia.
Though metformin crosses placenta, it is not teratogenic. There are no known adverse fetal effects. [8, 9] It can be continued for T2DM patients who are being treated preconceptionally.
The limitations of this study are that it is not a randomized controlled trial and the number of participants is small. Management may not have been consistent as the metformin and insulin groups were managed by two different consultants. We have not evaluated the longterm outcomes in infants exposed to metformin. However, the study by Glueck et al. has shown that neonatal outcomes have been good, with normal growth and development up to 18 months of life. [9] We monitored weekly sugar profi le as against the ideal daily self-monitoring of glucose. This was not possible due to the cost involved and reluctance on the part of patients. Nevertheless, there have been no major maternal or perinatal problems. Hence we feel, in resource-poor settings weekly glycemic profile is practical. Glycosylated hemoglobin, which gives an overall view of glucose control, also was not done in all patients.
The convenience and low cost of metformin may improve compliance when applied to a large population. Milder hyperglycemia of GDM in general responds well to metformin. In 2 patients, we had to add a small dose of insulin, late in the third trimester. As insulin requirement is small for this "add-on therapy," the cost is less. A clinical update on metformin therapy in pregnancy in Australia has recommended that metformin use may be considered as an adjunct or alternative to insulin therapy. [10] Though metformin use in pregnancy is not yet popular in India, a preliminary study by Ramachandran et al. reported it is useful either as an adjunct to insulin or even as a monotherapy. [11] 
CONCLUSION
We observed that glucose control was better and quicker with metformin than with insulin. Metformin therapy is practical and cheap compared to insulin. Our experience adds to the limited published literature in India on the use of metformin in GDM and T2DM. It is a useful fi rst-line therapy that is practical in resource-poor settings.
